Abbott Labs (ABT) Shares Declined While Integrys Wealth Advisors Has Cut Holding by $1.69 Million; Accenture LTD (ACN) Holder Suncoast Equity Management Cut Position as Market Valuation Declined

January 19, 2018 - By Migdalia James

Integrys Wealth Advisors Llc decreased its stake in Abbott Labs (ABT) by 14.78% based on its latest 2017Q3 regulatory filing with the SEC. Integrys Wealth Advisors Llc sold 31,873 shares as the company’s stock declined 3.42% while stock markets rallied. The institutional investor held 183,835 shares of the major pharmaceuticals company at the end of 2017Q3, valued at $9.81 million, down from 215,708 at the end of the previous reported quarter. Integrys Wealth Advisors Llc who had been investing in Abbott Labs for a number of months, seems to be less bullish one the $103.62 billion market cap company. The stock increased 0.78% or $0.46 during the last trading session, reaching $59.53. About 2.28 million shares traded. Abbott Laboratories (NYSE:ABT) has risen 15.90% since January 19, 2017 and is uptrending. It has underperformed by 0.80% the S&P500.

Suncoast Equity Management decreased its stake in Accenture Ltd (ACN) by 1.25% based on its latest 2017Q3 regulatory filing with the SEC. Suncoast Equity Management sold 2,525 shares as the company’s stock declined 0.21% while stock markets rallied. The institutional investor held 198,828 shares of the business services company at the end of 2017Q3, valued at $26.86 million, down from 201,353 at the end of the previous reported quarter. Suncoast Equity Management who had been investing in Accenture Ltd for a number of months, seems to be less bullish one the $99.22 billion market cap company. The stock decreased 0.03% or $0.05 during the last trading session, reaching $160.89. About 493,978 shares traded. Accenture plc (NYSE:ACN) has risen 4.27% since January 19, 2017 and is uptrending. It has underperformed by 12.43% the S&P500.

Suncoast Equity Management, which manages about $229.33M and $344.37M US Long portfolio, upped its stake in Home Depot (NYSE:HD) by 33,604 shares to 75,974 shares, valued at $12.43M in 2017Q3, according to the filing.

Investors sentiment decreased to 1 in 2017 Q3. Its down 0.05, from 1.05 in 2017Q2. It fall, as 40 investors sold ACN shares while 370 reduced holdings. 97 funds opened positions while 315 raised stakes. 461.53 million shares or 1.06% less from 466.45 million shares in 2017Q2 were reported. Annex Advisory Svcs Limited Liability has 0.25% invested in Accenture plc (NYSE:ACN) for 8,980 shares. 14,760 are held by Conning. Peddock Advsrs Ltd Liability Corporation reported 701 shares or 0.05% of all its holdings. Novare Capital Ltd Liability reported 0.98% in Accenture plc (NYSE:ACN). Cincinnati Casualty invested in 15,000 shares. Guyasuta Investment Advsrs has invested 0.09% in Accenture plc (NYSE:ACN). Trust Com Of Oklahoma reported 26,711 shares. Atlanta Management L L C has invested 0.44% in Accenture plc (NYSE:ACN). Guggenheim Cap Ltd Limited Liability Company has 0.14% invested in Accenture plc (NYSE:ACN) for 440,916 shares. West Coast Fincl Ltd Liability Co holds 0.39% or 10,633 shares in its portfolio. 1.04 million were reported by Rhumbline Advisers. Sequoia Fincl Advisors Llc holds 3,379 shares or 0.05% of its portfolio. Citigroup Inc has invested 0.04% in Accenture plc (NYSE:ACN). Crestwood Grp Incorporated Lc stated it has 15,505 shares. Fiduciary Mngmt Wi holds 5.44% of its portfolio in Accenture plc (NYSE:ACN) for 6.80M shares.

Among 26 analysts covering Accenture Plc (NYSE:ACN), 14 have Buy rating, 1 Sell and 11 Hold. Therefore 54% are positive. Accenture Plc had 88 analyst reports since August 12, 2015 according to SRatingsIntel. Barclays Capital maintained the shares of ACN in report on Monday, March 28 with “Equalweight” rating. The stock of Accenture plc (NYSE:ACN) has “Equalweight” rating given on Thursday, July 7 by Barclays Capital. The firm has “Buy” rating given on Monday, March 21 by Stifel Nicolaus. On Friday, July 28 the stock rating was maintained by Cowen & Co with “Buy”. The firm earned “Buy” rating on Monday, May 29 by Cantor Fitzgerald. The firm has “Market Perform” rating given on Friday, September 29 by BMO Capital Markets. The firm has “Buy” rating by Stifel Nicolaus given on Friday, May 20. As per Friday, December 22, the company rating was maintained by Cowen & Co. The firm has “Hold” rating by BMO Capital Markets given on Thursday, June 22. The firm has “Buy” rating given on Tuesday, September 8 by Argus Research.

Among 25 analysts covering Abbott Laboratories (NYSE:ABT), 18 have Buy rating, 0 Sell and 7 Hold. Therefore 72% are positive. Abbott Laboratories had 92 analyst reports since July 24, 2015 according to SRatingsIntel. Cowen & Co maintained it with “Buy” rating and $55.0 target in Friday, September 22 report. The stock of Abbott Laboratories (NYSE:ABT) earned “Buy” rating by Jefferies on Wednesday, October 18. The company was upgraded on Friday, February 5 by Argus Research. BMO Capital Markets maintained it with “Hold” rating and $53.0 target in Monday, October 2 report. Stifel Nicolaus maintained it with “Buy” rating and $58 target in Thursday, July 23 report. The stock has “Buy” rating by Gabelli on Friday, July 21. The firm earned “Hold” rating on Monday, July 10 by BMO Capital Markets. The stock of Abbott Laboratories (NYSE:ABT) earned “Overweight” rating by Barclays Capital on Wednesday, October 7. RBC Capital Markets maintained it with “Outperform” rating and $50 target in Wednesday, March 1 report. The stock has “Hold” rating by BMO Capital Markets on Thursday, August 31.

Since August 1, 2017, it had 0 insider purchases, and 6 selling transactions for $22.86 million activity. Contreras Jaime sold $2.74 million worth of Abbott Laboratories (NYSE:ABT) on Friday, September 22. $98,323 worth of stock was sold by Bracken Sharon J on Tuesday, August 1. 196,550 shares were sold by Fussell Stephen R, worth $9.73 million.

Analysts await Abbott Laboratories (NYSE:ABT) to report earnings on January, 24 before the open. They expect $0.73 earnings per share, up 12.31% or $0.08 from last year’s $0.65 per share. ABT’s profit will be $1.27B for 20.39 P/E if the $0.73 EPS becomes a reality. After $0.66 actual earnings per share reported by Abbott Laboratories for the previous quarter, Wall Street now forecasts 10.61% EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts